Management of difficult-to-treat inhibitor patients

Haemophilia

Volumn 16, Issue SUPPL. 3, 2010, Pages 52-57

  Giangrande, P L F ^a   Escobar, M A ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Difficult to treat; Haemophilia; Haemophilia with inhibitors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; TRANEXAMIC ACID;

ANTIBODY TITER; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; LOADING DRUG DOSE; LOW DRUG DOSE; NONHUMAN; PARAPLEGIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETREATMENT; SINGLE DRUG DOSE; SPINAL HEMATOMA; TREATMENT INDICATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; JOINT DISEASES; MALE; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 77953531928     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02261.x     Document Type: Article

References (23)

1. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006, 12:154-62.
2. Darby SC, Keeling DM, Spooner RJ. The incidence of factor VIII and factor IX inhibitors in the haemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004, 2:1047-54.
3. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003, 102:2358-63.
4. Jiménez-Yuste V, Alvarez MT, Martín-Salces M. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009, 15:203-9.
5. Valentino LA. The benefits of prophylactic treatment with aPCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia 2009, 15:733-42.
6. Hoots WK, Ebbesen LS, Konkle BA. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008, 14:466-75.
7. Konkle BA, Ebbesen LS, Erhardtsen E. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007, 5:1904-13.
8. Morfini M, Auerswald G, Kobelt RA. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007, 13:502-7.
9. Giangrande PL. Treatment of patients with haemophilia and inhibitory antibodies. Indian J Pediatr 2003, 70:655-9.
10. Salaj P, Brabec P, Penka M. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009, 15:752-9.
11. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999, 104:22-6.
12. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998, 63:7-10.
13. Rodriguez-Merchan EC. Prevention of haemophilic arthropathy in haemophilic children with inhibitors. Haemophilia 2008, 14(Suppl. 6):1-3.
14. Complementary and Alternative Medicine Index (CAM). http://www.umm.edu/altmed/articles/hemophilia-000076.htm, Available at Accessed October 17, 2009
15. Young G. New approaches in the management of inhibitor patients. Acta Haematol 2006, 115:172-9.
16. Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008, 14(Suppl. 6):20-2.
17. Morfini M, Haya S, Tagariello G. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007, 13:606-12.
18. Pivalizza EG, Escobar MA. Thromboelastography-guided factor VIIa therapy in a surgical patient with severe hemophilia and factor VIII inhibitor. Anesth Anal 2008, 107:398-401.
19. Tengborn L. Fibrinolytic Inhibitors in the Management of Bleeding Disorders 2007, Canada, WFH publication, Treatment of Hemophilia No. 42, April
20. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004, 10:347-51.
21. von Heymann C, Ziemer S, Kox WJ, Spies C. Caveat against the use of FEIBA in combination with recombinant factor VIIa. J Thorac Cardiovasc Surg 2002, 124:852-4.
22. Mizon P, Goudemand J, Jude B, Marey A. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. Ann Hematol 1992, 64:309-11.
23. Curry NS, Misbah SA, Giangrande PL, Keeling DM. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction. Haemophilia 2007, 13:328-30.